

By: Jeffrey D. Blake, Esq.  
Matthew L. Fedowitz, Esq.  
MERCHANT & GOULD P.C.  
191 Peachtree Street N.E., Suite 3800  
Atlanta, GA 30303  
jblake@merchantgould.com  
mfedowitz@merchantgould.com  
Main Telephone: (404) 954-5100  
Main Facsimile: (404) 954-5099

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COALITION FOR AFFORDABLE DRUGS II LLC  
Petitioner

v.

NPS PHARMACEUTICALS, INC.  
Patent Owner

---

Case No. IPR2015-00990  
Patent No. 7,056,886

---

**PETITIONER'S RESPONSE TO MOTION PRESENTING PATENT  
OWNER'S OBSERVATIONS REGARDING CROSS-EXAMINATION OF  
ANTHONY PALMIERI, Ph.D.**

## I. INTRODUCTION

The Coalition for Affordable Drugs II LLC (“Petitioner”) submits this Response to the Motion Presenting Patent Owner’s Observations Regarding Cross-Examination of Anthony Palmieri, Ph.D. (Paper 47, “Observations”). These responses to observations are timely submitted pursuant to a joint stipulation between the parties resetting the due date for these responses to May 31, 2016.

On May 27, 2016, a teleconference between the Board and the parties was held to provide guidance on how Petitioner should respond to Patent Owner’s improper Observations. During the teleconference, the Board authorized Petitioner to include an introduction in its Response to Patent Owner’s Observations explaining Petitioner’s objections and stating the relevant authority for those objections.

### A. Patent Owner’s Observations are an Unauthorized Sur-Reply

The Trial Practice Guide, 77 Fed. Reg. 157, 48756-73 (August 14, 2012) clearly explains the purpose of observations on cross-examination is to draw the Board’s attention to relevant cross-examination testimony that “occurs after a party has filed its last substantive paper on an issue.” *Chums, Inc. v. Cablz, Inc.* IPR2014-01240, Paper 32, page 2. The Trial Practice Guide, 77 Fed. Reg. 157, 48756-73 (August 14, 2012) sets forth requirements for observations on cross-examination.

An observation should be a concise statement of the relevance of identified testimony to an identified argument or portion of an exhibit (including another part of the same testimony)...An observation...is not an opportunity to raise new issues, re-argue issues, or pursue objections. Each observation should be in the following form:

In exhibit \_\_, on page \_\_, lines \_\_, the witness testified \_\_. This testimony is relevant to the \_\_ on page \_\_ of \_\_. The testimony is relevant because \_\_.

Rather than following the Trial Practice Guide, Patent Owner instead filed Observations that are in the improper format, excessively long, argumentative, and attempt to introduce new exhibits into the record. These Observations amount to an unauthorized sur-reply filed under the veil of Observations. If Patent Owner wished to respond to arguments in the Petitioner's reply, the proper mechanism was to contact the Board and request permission for a sur-reply. Patent Owner chose not to do so, and it should not be allowed to submit a sur-reply through improper observations. *See Medtronic, Inc. v. NuVasive, Inc.*, IPR2013-00506, Paper 37.

## **B. Requirements for Filing Observations**

Each of the Observations provided for Dr. Palmieri do not follow the format required by the Trial Practice Guide as set forth above. *See Observations 1-33.*

Instead, Patent Owner's Observations attempt to masquerade as being in the proper format by using phrases and terms such as "the witness testified" and "relevant." However, a cursory review of Dr. Palmieri's Observations reveal that they do not follow the Board's required format. *Id.*

The same is true regarding the argumentative nature of Patent Owner's Observations, which resemble a brief and are an attempt to introduce new evidence, re-argue issues and raise new issues. *See* Observation 3 arguing that Dr. Palmieri "misstated that Dr. Carpenter agreed that a formulator would not need to know formulation basics and would consult others for basics"; Observations 24 and 25 arguing that the identified testimony "evidences [Dr. Palmieri's] lack of expertise and his use of hindsight"; and Observation 32 raising the new issue that "Petitioner attempts to raise enablement issues in these IPRs."

This is improper as the Board is clear in its requirements that observations must be a concise statement of the relevance of precisely identified testimony to a precisely identified argument or portion of an exhibit. *Medtronic, Inc. v. NuVasive, Inc.*, IPR2013-00506, Paper 37, p. 2. In addition, the entire observation should not exceed one short paragraph. *Id.* Patent Owner's Observations disregard this requirement. *See* Observations 1, 2, 5, 8, 9, 10, 12, 14, 15, 18, 20, 22, and 27.

Further, each observation should cite to one portion of testimony and not several pages and this is a basis upon which observations may be

dismissed. *Medtronic, Inc. v. NuVasive, Inc.*, IPR2013-00506, Paper 37, pp 3-4. Patent Owner also did not follow this requirement. For example, Observation 1 provides seventeen citations to Ex. 2171 (333:12-334:19; 487:22-498:1; 337:21-338:11; 629:15-630:20; 453:18-454:8; 426:13-18; 570:15-25; 602:25-603:4; 603:24-604:6; 622:12-624:5; 624:16-22; 632:22-633:4; 605:12-606:2; 606:13-607:5; 611:19-613:13; 617:15-618:5; and 692:3-696:7). In fact, many citations are to extended portions of deposition transcript spanning multiple pages, such as 333:12-334:19, 487:22-498:1, 622:12-624:5, 611:19-613:13, and 692:3-696:7 for Observation 1 alone. *See also* Observations 2-9, 12-18, 25, and 33 as additional examples of improperly providing citations to multiple portions of testimony in a similar manner as Observation 1.

The Board may refuse entry of excessively long or argumentative observations. Trial Practice Guide at p. 48768; and, *Medtronic, Inc. v. NuVasive, Inc.*, IPR2013-00506, Paper 37, p. 2. Indeed, the majority of Patent Owner's Observations are lengthy. *See* Observations 1, 2, 5, 8, 9, 10, 12, 14, 15, 18, 20, 22, and 27. The Board has precedent for dismissing excessively long observations. *Medtronic, Inc. v. NuVasive, Inc.*, IPR2013-00506, Paper 37, page 3.

Finally, the Board has held that no new exhibits are permitted with Observations by stating that *only* testimony from cross-examination should be present in Observations. *Medtronic, Inc. v. NuVasive, Inc.*, IPR2013-00506, Paper

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.